vs

Side-by-side financial comparison of Bioventus Inc. (BVS) and Jefferson Capital, Inc. (JCAP). Click either name above to swap in a different company.

Bioventus Inc. is the larger business by last-quarter revenue ($157.9M vs $150.8M, roughly 1.0× Jefferson Capital, Inc.). Jefferson Capital, Inc. runs the higher net margin — 25.4% vs 9.3%, a 16.1% gap on every dollar of revenue. Jefferson Capital, Inc. produced more free cash flow last quarter ($63.0M vs $37.4M).

Bioventus Inc. is a global medical technology company specializing in orthobiologic solutions. It develops and commercializes products supporting bone and joint healing, musculoskeletal pain management, and regenerative care for patients. Its offerings serve orthopedic clinicians, physical therapists, and patients across North America, Europe, and Asia Pacific, with core segments covering surgical orthobiologics and non-surgical pain relief solutions.

GE Capital was the financial services division of General Electric. Its various units were sold between 2013 and 2021, including the notable spin-off of the North American consumer finance division as Synchrony Financial. Ultimately, only one division of the company remained, GE Energy Financial Services, which was transferred to GE Vernova when General Electric was broken up.

BVS vs JCAP — Head-to-Head

Bigger by revenue
BVS
BVS
1.0× larger
BVS
$157.9M
$150.8M
JCAP
Higher net margin
JCAP
JCAP
16.1% more per $
JCAP
25.4%
9.3%
BVS
More free cash flow
JCAP
JCAP
$25.6M more FCF
JCAP
$63.0M
$37.4M
BVS

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BVS
BVS
JCAP
JCAP
Revenue
$157.9M
$150.8M
Net Profit
$14.8M
$38.4M
Gross Margin
68.9%
Operating Margin
12.3%
46.4%
Net Margin
9.3%
25.4%
Revenue YoY
2.8%
Net Profit YoY
3902.8%
EPS (diluted)
$0.21
$0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BVS
BVS
JCAP
JCAP
Q4 25
$157.9M
Q3 25
$138.7M
$150.8M
Q2 25
$147.7M
$152.7M
Q1 25
$123.9M
Q4 24
$153.6M
Q3 24
$139.0M
Q2 24
$151.2M
Q1 24
$129.5M
Net Profit
BVS
BVS
JCAP
JCAP
Q4 25
$14.8M
Q3 25
$3.2M
$38.4M
Q2 25
$7.5M
$47.7M
Q1 25
$-2.6M
Q4 24
$-388.0K
Q3 24
$-5.2M
Q2 24
$-25.7M
Q1 24
$-4.9M
Gross Margin
BVS
BVS
JCAP
JCAP
Q4 25
68.9%
Q3 25
68.0%
Q2 25
69.1%
Q1 25
67.0%
Q4 24
66.8%
Q3 24
67.3%
Q2 24
68.5%
Q1 24
68.3%
Operating Margin
BVS
BVS
JCAP
JCAP
Q4 25
12.3%
Q3 25
8.1%
46.4%
Q2 25
12.4%
56.7%
Q1 25
3.9%
Q4 24
5.0%
Q3 24
2.6%
Q2 24
-20.8%
Q1 24
3.8%
Net Margin
BVS
BVS
JCAP
JCAP
Q4 25
9.3%
Q3 25
2.3%
25.4%
Q2 25
5.1%
31.2%
Q1 25
-2.1%
Q4 24
-0.3%
Q3 24
-3.7%
Q2 24
-17.0%
Q1 24
-3.8%
EPS (diluted)
BVS
BVS
JCAP
JCAP
Q4 25
$0.21
Q3 25
$0.05
$0.59
Q2 25
$0.11
$16.76
Q1 25
$-0.04
Q4 24
$0.00
Q3 24
$-0.08
Q2 24
$-0.40
Q1 24
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BVS
BVS
JCAP
JCAP
Cash + ST InvestmentsLiquidity on hand
$51.2M
$42.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$184.1M
$437.4M
Total Assets
$683.6M
$1.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BVS
BVS
JCAP
JCAP
Q4 25
$51.2M
Q3 25
$42.2M
$42.3M
Q2 25
$32.9M
$51.7M
Q1 25
$22.8M
Q4 24
$41.6M
Q3 24
$43.1M
Q2 24
$32.0M
Q1 24
$25.2M
Stockholders' Equity
BVS
BVS
JCAP
JCAP
Q4 25
$184.1M
Q3 25
$166.1M
$437.4M
Q2 25
$161.2M
$410.8M
Q1 25
$148.1M
Q4 24
$147.9M
Q3 24
$148.7M
Q2 24
$150.9M
Q1 24
$171.3M
Total Assets
BVS
BVS
JCAP
JCAP
Q4 25
$683.6M
Q3 25
$701.6M
$1.8B
Q2 25
$706.8M
$1.8B
Q1 25
$691.4M
Q4 24
$728.0M
Q3 24
$769.5M
Q2 24
$792.2M
Q1 24
$794.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BVS
BVS
JCAP
JCAP
Operating Cash FlowLast quarter
$38.0M
$63.1M
Free Cash FlowOCF − Capex
$37.4M
$63.0M
FCF MarginFCF / Revenue
23.7%
41.7%
Capex IntensityCapex / Revenue
0.4%
0.1%
Cash ConversionOCF / Net Profit
2.57×
1.64×
TTM Free Cash FlowTrailing 4 quarters
$72.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BVS
BVS
JCAP
JCAP
Q4 25
$38.0M
Q3 25
$30.1M
$63.1M
Q2 25
$25.9M
$130.6M
Q1 25
$-19.3M
Q4 24
$19.3M
Q3 24
$10.3M
Q2 24
$15.2M
Q1 24
$-6.0M
Free Cash Flow
BVS
BVS
JCAP
JCAP
Q4 25
$37.4M
Q3 25
$29.6M
$63.0M
Q2 25
$25.3M
$130.0M
Q1 25
$-20.2M
Q4 24
$18.7M
Q3 24
$10.3M
Q2 24
$15.1M
Q1 24
$-6.3M
FCF Margin
BVS
BVS
JCAP
JCAP
Q4 25
23.7%
Q3 25
21.4%
41.7%
Q2 25
17.1%
85.1%
Q1 25
-16.3%
Q4 24
12.2%
Q3 24
7.4%
Q2 24
10.0%
Q1 24
-4.9%
Capex Intensity
BVS
BVS
JCAP
JCAP
Q4 25
0.4%
Q3 25
0.3%
0.1%
Q2 25
0.5%
0.4%
Q1 25
0.7%
Q4 24
0.4%
Q3 24
0.0%
Q2 24
0.1%
Q1 24
0.2%
Cash Conversion
BVS
BVS
JCAP
JCAP
Q4 25
2.57×
Q3 25
9.54×
1.64×
Q2 25
3.48×
2.74×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BVS
BVS

Pain Treatments$71.1M45%
Surgical Solutions$48.9M31%
Restorative Therapies$19.5M12%
Other$18.4M12%

JCAP
JCAP

United States Segment$108.1M72%
Other$35.8M24%
United Kingdom Segment$6.9M5%

Related Comparisons